Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$68.02 - $99.06 $98.5 Million - $143 Million
-1,448,161 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$84.37 - $133.6 $33.5 Million - $53.1 Million
-397,592 Reduced 21.54%
1,448,161 $126 Million
Q2 2021

Aug 16, 2021

SELL
$64.12 - $128.71 $14.6 Million - $29.2 Million
-226,926 Reduced 10.95%
1,845,753 $238 Million
Q1 2021

May 17, 2021

SELL
$71.28 - $120.75 $63.7 Million - $108 Million
-893,724 Reduced 30.13%
2,072,679 $166 Million
Q1 2020

May 15, 2020

BUY
$13.31 - $29.2 $39.5 Million - $86.6 Million
2,966,403 New
2,966,403 $53.4 Million

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.65B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Hhlr Advisors, Ltd. Portfolio

Follow Hhlr Advisors, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hhlr Advisors, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Hhlr Advisors, Ltd. with notifications on news.